Takakura Will R, Tabibian James H, Bowlus Christopher L
aEastern Virginia Medical School, Norfolk, Virginia bDivision of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California, USA.
Curr Opin Gastroenterol. 2017 Mar;33(2):71-77. doi: 10.1097/MOG.0000000000000333.
Primary sclerosing cholangitis (PSC) is a rare, idiopathic biliary disease often with an insidious onset, variable disease course, and premature death related to benign and malignant PSC-related sequelae. This review aims to discuss the epidemiology, clinical variants, and natural history of PSC, incorporating data from recent population-based studies.
PSC naturally leads to cirrhosis, cholangiocarcinoma, other hepatobiliary malignancies, dominant strictures, hepatic osteodystrophy, and bacterial cholangitis. The incidence of PSC appears to be increasing, the reasons for which are unclear. The time from diagnosis to liver transplant appears to be longer in more recent studies compared with earlier studies, suggesting a better overall prognosis than previously believed. In addition, with an increasing number of patients undergoing liver transplantation for PSC, the frequency of death because of liver failure has decreased, whereas cancer-related deaths have increased among patients with PSC.
PSC is a heterogeneous disease with a variety of clinical outcomes, both fatal and nonfatal. The progression of liver fibrosis in an individual patient is difficult to predict and may vary from a relatively benign, nonprogressive form to a rapidly progressive form with the need for liver transplantation.
原发性硬化性胆管炎(PSC)是一种罕见的特发性胆道疾病,通常起病隐匿,病程多变,与PSC相关的良性和恶性后遗症可导致过早死亡。本综述旨在结合近期基于人群研究的数据,讨论PSC的流行病学、临床变异型及自然史。
PSC自然病程会导致肝硬化、胆管癌、其他肝胆恶性肿瘤、主导管狭窄、肝性骨营养不良和细菌性胆管炎。PSC的发病率似乎在上升,原因尚不清楚。与早期研究相比,近期研究中从诊断到肝移植的时间似乎更长,提示总体预后比之前认为的要好。此外,随着越来越多的PSC患者接受肝移植,因肝衰竭死亡的频率有所下降,而PSC患者中与癌症相关的死亡有所增加。
PSC是一种具有多种临床结局(包括致命和非致命结局)的异质性疾病。个体患者肝纤维化的进展难以预测,可能从相对良性、非进行性形式到需要肝移植的快速进行性形式不等。